Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00001452|
Recruitment Status : Completed
First Posted : November 4, 1999
Last Update Posted : June 2, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Lentiginosis refers to groups of diseases marked by the presence of pigmented spots on the skin. These conditions are most commonly associated with multiple tumors and changes in hormone producing glands. The cause of these diseases is unknown, but researchers suggest there may be a level of inheritance involved in their development. Meaning to say that some of these diseases may "run in the family" and be passed down form generation to generation.
Primary pigmented nodular adrenocortical disease (PPNAD) is a pituitary-independent, primary adrenal form of hypercortisolism characterized by;
- Resistance to suppression by the drug dexamethasone
- The body is unable to secrete cortisol in a normal rhythm
- Distinct microscopic changes of both adrenal glands
PPNAD can be associated with tumors (myxomas) of the skin, heart, breast, tumors (swannomas) of the nerve sheaths, pigmented spots (nevi and lentigines) of the skin, growth hormone (GH) producing tumors of the pituitary gland, and tumors of the testicles, ovaries, and thyroid gland. In the presence of these associations the condition is referred to as the Carney Complex. Presently there are no tests for screening of PPNAD and the Carney Complex. In addition, it is unknown how these conditions are genetically transferred from generation to generation.
This study proposes to use standard methods of clinical testing for endocrine and nonendocrine diseases and genetic testing in order to;
- Define the genetic basis for PPNAD and/or the Carney Complex.
- Determine the molecular changes associated with the development of the tumors.
- Identify carriers of the disease.
- Determine the prognosis for carriers and affected individuals.
- Provide sufficient data for genetic counseling of families with PPNAD and/or Carney Complex.<TAB>...
|Condition or disease||Intervention/treatment|
|Cushing's Syndrome Pituitary Adenoma Carney Complex Primary Pigmented Nodular Adrenocortical Disease Peutz-Jeghers Syndrome||Drug: oCRH|
|Study Type :||Observational|
|Actual Enrollment :||1387 participants|
|Official Title:||Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related Conditions|
|Actual Study Start Date :||December 14, 1995|
families with PPNAD and/or Carney complex
- Genotype and clinical phenotype correlation in patients with PPNAD, Carney Complex, Peutz-Jeghers Syndrome and related conditions. [ Time Frame: This is an ongoing project ]Genotype and clinical phenotype correlation in patients with PPNAD, Carney Complex, Peutz-Jeghers Syndrome and related conditions.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||3 Years to 70 Years (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
All patients with PPNAD and/or Carney Complex by history and their siblings, children and parents. Additional relatives and their families that are suspected to have the same disorder on clinical grounds will be recruited:
- PPNAD patients will be included if their diagnosis is fully documented. First-degree relatives of patients with the disease will be accepted also for evaluation, or if already conclusively evaluated elsewhere, for DNA linkage analysis only.
- Patients with suspected Carney complex will be accepted for evaluation and/or DNA analysis for linkage, if they have at least two of the following:
- cardiac myxoma
- cutaneous myxoma
- breast myxoma
- oral myxoma
- myxoma of the external ear
- spotty mucocutaneous pigmentation (lentigines)
- testicular tumor
- pituitary growth hormone secreting adenoma
- nerve tumor, such as psammomatous melanotic schwannoma
first-, second-, or third-degree relatives with Carney complex
(c) Patients with one of the familial lentiginosis syndromes: Peutz-Jeghers and LEOPARD syndrome, other forms of familial lentiginosis.
For DNA analysis and linkage study:
1. Unwillingness to participate.
For clinical evaluation and DNA analysis/linkage study:
- Patients with major illnesses, such as severe renal failure, restrictive or obstructive lung disease, cardiac disease, anemia and/or terminal cancer that will not be able to undergo appropriate testing or the stress of hospitalization. Also, patients with Carney complex and a known heart tumor (heart myxoma) will not be able to enter the clinical part of the study until after surgical treatment of their tumor. These patients, however, will be asked to participate in the DNA analysis study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001452
|United States, Maryland|
|National Institutes of Health Clinical Center|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Crystal D Kamilaris, M.D.||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|
|Other Study ID Numbers:||
|First Posted:||November 4, 1999 Key Record Dates|
|Last Update Posted:||June 2, 2023|
|Last Verified:||May 9, 2023|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Adrenal Gland Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplastic Syndromes, Hereditary